adaptive biotechnologies stock news
ET by Ciara Linnane Adaptive Biotechnologies Corp. Seattle may 02 2022 globe newswire -- adaptive biotechnologies corporation adaptive biotechnologies nasdaq.
Adaptive S T Detect Covid Test Cleared For Emergency Use In Us Shares Pop 18
The stock is currently down 753 year-to-date down 805 over the past 12 months and.
. Adaptive Biotechnologies ADPT Reports Q1 Loss Lags Revenue Estimates Adaptive Biotechnologies ADPT delivered earnings and revenue surprises of -233 and 026 respectively for the quarter. Volume today is low. Adaptive Biotechnologies News Headlines 824 136 1977 As of 05132022 0400 PM ET Todays Range 708 827 50-Day Range 650 1473 52-Week Range 620 4340 Volume 199 million shs Average Volume 162 million shs Market Capitalization 117 billion PE Ratio NA Dividend Yield NA Beta 107 Profile Analyst Ratings Chart.
Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes. Heres a mini-portfolio of innovative companies trading under 10 a share right now. Engages in the development of an immune.
Adaptive Biotech launches 8M-share stock offering SA News Tue Jul. For the readers interested in the stock health of Adaptive Biotechnologies Corporation ADPT. It is currently valued at 799.
8 brokers have issued 12 month price objectives for Adaptive Biotechnologies shares. The stock has fallen by -7153 since the beginning of the year thereby showing the potential of a further growth. June 2 2022 - 410 pm.
According to data from MarketBeat the stock presently has a consensus rating of Buy and an average price target of 3017. 2 days agoAdaptive Biotechnologies currently has a consensus target price of 2980 indicating a potential upside of 27297. Companys stock value dipped to 717 during the trading on the day.
Adpt a commercial stage biotechnology company that aims to. Their forecasts range from 1000 to 5000. SEATTLE June 02 2022 GLOBE NEWSWIRE -- Data from Adaptive Biotechnologies Corporation Nasdaq.
The number of short shares registered in Apr 13 2022 reached 532 million. Adaptive Biotechnologies Corp ADPT shares closed today 131 lower than it did at the end of yesterday. Adaptive Biotechnologies Corp ADPT stock is trading at 710 as of 1123 AM on Friday Jun 3 a decline of -089 or -112 from the previous closing price of 799.
The stock closed at 822 per share. Get the latest news and real-time alerts from Adaptive Biotechnologies Corporation ADPT stock at Seeking Alpha. SEATTLE June 02 2022 GLOBE NEWSWIRE -- Data from Adaptive Biotechnologies Corporation Nasdaq.
Morgan Thinks Adaptive Biotechnologies Stock is Going to Recover May 25. ADPT a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune. Because of this stock market crash some wonderful stocks are super cheap in 2022.
IN8bio has a consensus target price of 1050 indicating a potential upside of. So its worth taking a look at the surprise history for gauging its influence on the upcoming numberfor the last reported quarter it was expected that adaptive biotechnologies would post a loss. So far 555936 shares have traded compared to average volume of 1662574 shares.
This suggests a possible upside of 2730 from the stocks current price. Latest On Adaptive Biotechnologies Corp There is no recent news for this security. ADPT stock opened at 822 on Tuesday.
The stock was sold at an average. On average they expect Adaptive Biotechnologies stock price to reach 2980 in the next year. 27 2019 at 815 am.
When the transactions were called off in the previous session Stock hit the highs of 815 after setting-off with the price of 725. Adaptive Biotechnologies Corporation NASDAQADPT delivered a -7071 return since the beginning of the year while its 12-month returns are down by -7826. Content From Our Affiliates JP.
According to the data the short interest in Adaptive Biotechnologies Corporation ADPT stood at 486 of shares outstanding as of May 12 2022. SA Transcripts Wed May 04 Adaptive Biotechnologies GAAP EPS of -044 in-line revenue of 386M beats by 089M SA NewsWed May 04 Adaptive Biotechnologies Corporation SEC Filing - Quarterly. The stock has traded between 708 and 786 so far today.
In other Adaptive Biotechnologies news President Julie Rubinstein sold 4613 shares of the companys stock in a transaction that occurred on Monday March 7th. ADPT a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical. ADPT a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical.
Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes. Adaptive Biotech prices IPO at 20 a share Jun. SEATTLE June 02 2022 GLOBE NEWSWIRE -- Data from Adaptive Biotechnologies Corporation Nasdaq.
2 days agoData demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes.
Adaptive Biotechnologies Nasdaq Adpt Announces Earnings Results Beats Expectations By 0 01 Eps Defense World
Kkr Real Estate Finance Trust Inc Announces Record Annual And Fourth Quarter 2021 Originations Of 4 8 Billion And 1 8 Billion Respectively 2022
Jusulhg Hu0dgm
Adaptive Biotechnologies Nasdaq Adpt Shareholders Incur Further Losses As Stock Declines 4 1 This Week Taking One Year Losses To 54 Nasdaq
Mxsa09mu7h2nlm
Biotech Stocks Are Getting Crushed But Industry Insiders Say There S Reason For Optimism Best Technologies
Adaptive Biotechnologies Adpt Stock Price Quote News Analysis Tipranks
Adaptive Biotechnologies Adpt Stock Price Quote News Analysis Tipranks
Adaptive Biotechnologies Corporation Adpt Stock Price Quote News Stock Analysis
Is Adaptive Biotechnologies Corporation Adpt A Good Stock To Buy
Mxsa09mu7h2nlm
Adaptive Biotechnologies Reports Fourth Quarter And Full Year 2021 Financial Results
Adpt Adaptive Biotechnologies Corp Stock Overview U S Nasdaq Barron S
Biotech Stocks Are Getting Crushed But Industry Insiders Say There S Reason For Optimism Geekwire
Bears Are Losing Control Over Adaptive Biotechnologies Adpt Here S Why It S A Buy Now
Mxsa09mu7h2nlm
Mxsa09mu7h2nlm
Adaptive Biotechnologies Good Buy For Long Term Investors Adpt Seeking Alpha
Pin On Stock Market